Wednesday July 8, 9:56 am Eastern Time

Trinity Biotech Extends Class B Warrants

DUBLIN, Ireland--(BW HealthWire)--July 8, 1998--Trinity Biotech plc (NASDAQ:TRIBY) today announced that its board of directors has decided, effective immediately, to extend the life of the Company's Class B Warrants from October 22, 1998 to February 28, 1999. The Company also reported that the exercise price of the Class B Warrants will be reduced from $4.00 to $3.00.

Each Class B Warrant entitles the holder to purchase, at a price of $3.00, one Class A ordinary share (ADR) of Trinity Biotech plc. The Class B Warrant now expires on February 28, 1999. Any Class B Warrant which has not been exercised prior to February 28, 1999 will expire and will no longer be exercisable. Holders of the Class B Warrants who wish to exercise their Class B Warrant and thus avoid expiration must:

1.   Complete and sign the subscription form on the reverse of the
     Warrant Certificate; and

2.   Submit (or have their broker submit), the Warrant Certificate and
     payment of exercise price ($3.00 per share) to arrive at the
     Warrant Agent's office (Bank of New York, 101 Barclay Street, New
     York, NY 10286) no later than 5:00 p.m. (Eastern Standard Time)
     on February 28, 1999. Failure to do so will result in the loss of
     any further right to exercise the Class B Warrant.

Trinity Biotech develops, manufactures, and markets over 100 diagnostic products for the point-of-care (POC), self testing (OTC), and clinical laboratory segments of the diagnostic market. Trinity sells worldwide in over 75 countries through 130 international distributors and strategic partners including Warner Lambert, Carter Wallace, and SmithKline Beecham.

Forward-looking statements in this release are made pursuant to the ``safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Contact:

     Trinity Biotech plc        OTC Communications
     Jonathan O'Connell         Robert M. Joyce
     800-603-8076               888-32-TRIBY (87429) ext. 11
     www.trinitybiotech.com     www.otcfn.com/triby

Back to Press Releases